Skip to main content
NCBI home page
British Journal of Clinical Pharmacology logoLink to British Journal of Clinical Pharmacology
. 1987 Sep;24(3):359–366. doi: 10.1111/j.1365-2125.1987.tb03181.x

Peripheral vascular effects of beta-adrenoceptor blockade: comparison of two agents.

E D Cooke 1, M B Maltz 1, R E Smith 1, S A Bowcock 1, C J Watkins 1, A J Camm 1
PMCID: PMC1386258  PMID: 2889459

Abstract

1. The effects of atenolol (100 mg), a beta 1-adrenoceptor blocker, and bevantolol (200 mg) were compared on heart rate, blood pressure, lung function and on the peripheral circulation in normal volunteers before and after isoprenaline infusion. Recordings were obtained 2 and 24 h following a single dose and 24 h after continuous dosage for 7 days. 2. The effect of atenolol on the blockade of beta-adrenergic stimuli, as measured by the ability to reduce isoprenaline-induced tachycardia, was greater than that of bevantolol. Though both drugs achieved a similar reduction in systolic pressure there was a significantly greater reduction in diastolic pressure with bevantolol. The lung function tests gave similar results to those with other beta-adrenoceptor blockers. 3. Atenolol produced a fall in peripheral blood flow consistent with unopposed peripheral alpha-adrenoceptor stimulation. The effect of bevantolol differs from that of atenolol, an initial fall in peripheral blood flow being followed by a rapid recovery to baseline or greater. This effect may be due to partial alpha-adrenoceptor agonist activity.

Full text

PDF
359

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Al-Khawaja I. M., Caruana M. P., Prince H., Whittington J., Raftery E. B. Once- and twice-daily bevantolol for systemic hypertension using 24-hour ambulatory intraarterial blood pressure recording. Am J Cardiol. 1986 Nov 26;58(12):17E–20E. doi: 10.1016/0002-9149(86)90592-8. [DOI] [PubMed] [Google Scholar]
  2. Bennett T., Hosking D. J., Hampton J. R. Cardiovascular responses to lower body negative pressure in normal subjects and in patients with diabetes mellitus. Cardiovasc Res. 1979 Jan;13(1):31–38. doi: 10.1093/cvr/13.1.31. [DOI] [PubMed] [Google Scholar]
  3. Benson M. K. Cardioselectivity studies. Proc R Soc Med. 1977;70(Suppl 5):48–49. doi: 10.1177/00359157770700S520. [DOI] [PMC free article] [PubMed] [Google Scholar]
  4. CONWAY J. A vascular abnormality in hypertension. A study of blood flow in the forearm. Circulation. 1963 Apr;27(4 Pt 1):520–529. doi: 10.1161/01.cir.27.4.520. [DOI] [PubMed] [Google Scholar]
  5. Cooke E. D., Bowcock S. A., Smith A. T. Cold sensitivity in essential hypertension: the effect of beta- and combined alpha- and beta-blockade. Eur J Clin Pharmacol. 1985;29(1):33–36. doi: 10.1007/BF00547365. [DOI] [PubMed] [Google Scholar]
  6. Cooke E. D., Bowcock S. A., Smith A. T. Photoplethysmography of the distal pulp in the assessment of the vasospastic hand. Angiology. 1985 Jan;36(1):33–40. doi: 10.1177/000331978503600106. [DOI] [PubMed] [Google Scholar]
  7. Dukes I. D., Vaughan Williams E. M. Cardiovascular effects of bevantolol, a selective beta 1-adrenoceptor antagonist with a novel pharmacological profile. Br J Pharmacol. 1985 Feb;84(2):365–380. doi: 10.1111/j.1476-5381.1985.tb12921.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  8. FOLKOW B., GRIMBY G., THULESIUS O. Adaptive structural changes of the vascular walls in hypertension and their relation to the control of the peripheral resistance. Acta Physiol Scand. 1958 Dec 15;44(3-4):255–272. doi: 10.1111/j.1748-1716.1958.tb01626.x. [DOI] [PubMed] [Google Scholar]
  9. Fairhurst G. J. Comparison of bevantolol and atenolol for systemic hypertension. Am J Cardiol. 1986 Nov 26;58(12):25E–27E. doi: 10.1016/0002-9149(86)90594-1. [DOI] [PubMed] [Google Scholar]
  10. Gokal R., Dornan T. L., Ledingham J. G. Peripheral skin necrosis complicating beta-blockage. Br Med J. 1979 Mar 17;1(6165):721–722. doi: 10.1136/bmj.1.6165.721-a. [DOI] [PMC free article] [PubMed] [Google Scholar]
  11. Latts J. R. Clinical pharmacokinetics and metabolism of bevantolol. Angiology. 1986 Mar;37(3 Pt 2):221–225. doi: 10.1177/000331978603700313. [DOI] [PubMed] [Google Scholar]
  12. Salonen J. T., Taskinen E., Salonen R., Seppänen K., Venäläinen J., Rauramaa R. Effects of bevantolol and atenolol on symptoms, exercise tolerance and metabolic risk factors in angina pectoris. Am J Cardiol. 1986 Nov 26;58(12):35E–40E. doi: 10.1016/0002-9149(86)90596-5. [DOI] [PubMed] [Google Scholar]
  13. Schwender C. F., Pike R. E., Shavel J., Jr Beta-adrenergic blockade by 3-[3-(substituted amino)-2-hydroxypropox]-5-hydroxybenzyl alcohols. J Med Chem. 1975 Feb;18(2):211–213. doi: 10.1021/jm00236a024. [DOI] [PubMed] [Google Scholar]
  14. Vale J. A., Van de Pette S. J., Price T. M. Peripheral gangrene complicating beta-blockade. Lancet. 1977 Aug 20;2(8034):412–412. doi: 10.1016/s0140-6736(77)90354-3. [DOI] [PubMed] [Google Scholar]
  15. Zacharias F. J., Cowen K. J., Prestt J., Vickers J., Wall B. G. Propranolol in hypertension: a study of long-term therapy, 1964-1970. Am Heart J. 1972 Jun;83(6):755–761. doi: 10.1016/0002-8703(72)90206-2. [DOI] [PubMed] [Google Scholar]

Articles from British Journal of Clinical Pharmacology are provided here courtesy of British Pharmacological Society

RESOURCES